Table 3 Univariable and multivariable Cox‐proportional hazard model for disease-free survival in BCLC very-early stage hepatocellular carcinoma patients
Characteristics | Univariate Cox regression analyses | Multivariate Cox regression analyses | ||
|---|---|---|---|---|
Unadjusted HR (95% CI) | P-value | Adjusted HR (95% CI) | P-value | |
Treatment type (SR vs. RFA) | 1.35 (0.86–2.11) | 0.193 | ||
Male | 0.97 (0.60–1.56) | 0.903 | ||
Age (≥ 60y vs, < 60y) | 0.49 (0.31–0.76) | 0.002 | 0.47 (0.30–0.73) | 0.001 |
BMI (≥ 24 kg/m2 vs. < 24 kg/m2) | 1.29 (0.83–2.02) | 0.256 | ||
Alcohol use | 1.04 (0.63–1.72) | 0.871 | ||
HBV | 1.29 (0.83–2.03) | 0.256 | ||
HCV | 0.73 (0.47–1.14) | 0.164 | ||
Child‐Pugh class A | 1.14 (0.42–3.13) | 0.795 | ||
Cirrhosis | 0.59 (0.37–0.96) | 0.032 | 0.56 (0.35–0.90) | 0.018 |
Ascites | 0.76 (0.35–1.65) | 0.482 | ||
Total bilirubin (≥ 1.3 mg/dL vs. < 1.3 mg/dL) | 0.87 (0.52–1.47) | 0.609 | ||
Albumin (≥ 3.5 g/dL vs. < 3.5 g/dL) | 1.08 (0.50–2.36) | 0.840 | ||
ALBI grade 1 vs. 2/3 | 0.82 (0.39–1.70) | 0.589 | ||
AFP (≥ 200 ng/ml vs. < 200 ng/ml) | 0.78 (0.44–1.40) | 0.406 | ||
Tumor size (≥ 1.8 cm vs. < 1.8 cm) | 1.19 (0.75–1.87) | 0.467 | ||